secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001728117-23-000091
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio provides interim TORREY OLE data and PROSERA Phase 3 trial design
------------------------------------------------------------------------------

- Announced interim data from open-label extension of seralutinib in PAH patients.
- Detailed design of planned Phase 3 PROSERA trial for seralutinib.
- No specific efficacy or safety numbers disclosed in the filing or exhibit.
- Corporate presentation furnished as Exhibit 99.1 contains the update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000091/0001728117-23-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000091/goss-20230720.htm
  HTML page:      https://secwatch.observer/filing/0001728117-23-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer